duopharmabiotech.com Listed by ValenciaLeaks Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On 18 September 2024, the website duopharmabiotech.com appeared on a listing associated with the ValenciaLeaks ransomware group. Public details indicate that the group claims to have exfiltrated 25.7 GB of internal files, with a stated leak date of 23 August 2024. The number of people whose information may be involved remains unknown, and the precise contents of the files have not been independently confirmed. For anyone connected to the organisation—employees, partners, suppliers or patients—the practical concern is straightforward: internal business records can contain personal identifiers, contact details and operational data that, once outside the organisation’s control, can be misused for fraud, phishing or further intrusion.

Because the scale of individual impact is undisclosed, anyone who has shared personal or professional information with Duopharma Biotech or its related entities has reason to treat the claim seriously and take basic protective steps while fuller details remain limited.

Inside the incident

According to the available record, duopharmabiotech.com was listed by the ValenciaLeaks ransomware group on or around 18 September 2024. The group’s own summary states that 25.7 GB of data was exfiltrated and sets a leak date of 23 August 2024 at 04:00. The listing characterises the material as internal files obtained in a ransomware attack. No further technical description of the intrusion method, the systems affected, or the exact timeline of access has been made public. The number of individuals whose data may appear in the files is listed as unknown. Independent verification of the volume, the authenticity of the files, or the success of any encryption component of the attack has not been reported in the facts available.

In short, the incident is known primarily through the group’s claim of exfiltration and the subsequent listing. Timing of the initial compromise, the presence or absence of ransom negotiations, and any containment measures taken by the organisation remain undisclosed.

The group behind it: ValenciaLeaks

ValenciaLeaks is a ransomware operation that follows a familiar double-extortion pattern: after gaining access to a network, operators encrypt systems and simultaneously copy data, then threaten to publish the stolen material if payment is not made. Groups of this type typically maintain dedicated leak sites where they post victim names, sample files and countdown timers to pressure organisations. Public reporting on ValenciaLeaks has documented its use of these standard tactics across multiple sectors, including manufacturing, professional services and healthcare-related entities. The group’s listings are claims of compromise rather than independently verified admissions by the named organisations.

In the present case, the appearance of duopharmabiotech.com on the ValenciaLeaks site constitutes the group’s assertion that it holds 25.7 GB of internal files. No additional statements attributed specifically to ValenciaLeaks about this victim—beyond the volume and leak-date figures already noted—appear in the available facts. As with other ransomware listings, the claim should be treated as unverified until corroborated by the organisation or by forensic analysis.

duopharmabiotech.com and its sector

duopharmabiotech.com is the online presence of Duopharma Biotech, a pharmaceutical and biotechnology company. Organisations in this sector develop, manufacture and distribute medicines and related products. They routinely handle research data, manufacturing records, supply-chain information, employee personnel files, and, in many cases, information linked to clinical or commercial partners. Because pharmaceutical operations sit at the intersection of regulated health products and commercial intellectual property, the data they hold can include both commercially sensitive material and personal information about staff, contractors and, potentially, patients or trial participants.

A ransomware incident affecting such an organisation therefore carries consequences beyond ordinary business disruption. Even if the primary target is operational continuity, the secondary risk is the exposure of records that regulators, partners and individuals expect to remain confidential. Public knowledge of the sector makes clear that these companies are attractive targets precisely because of the dual value of their data—intellectual property that can be sold or leveraged, and personal data that can be exploited for identity-related crime.

The information in question

The facts state only that “internal files” were exfiltrated in a ransomware attack and that the claimed volume is 25.7 GB. No inventory of specific data types—such as names, identification numbers, medical records, financial details or intellectual-property documents—has been disclosed. Organisations of this kind typically maintain human-resources databases, vendor contracts, research documentation, quality-control records and correspondence. Whether any of those categories are present in the claimed 25.7 GB remains unconfirmed.

Because the exact contents are not publicly detailed, it is not possible to state with certainty which individuals or categories of information are affected. The prudent assumption for anyone who has interacted with the company is that personal or professional data could be among the files, but that assumption is not yet supported by a verified file listing.

Why it matters

For individuals, the principal risks are identity fraud, targeted phishing and the long-term reuse of personal details that may surface months or years later on criminal markets. Even limited internal files can contain enough contact information, employment history or authentication clues to enable convincing social-engineering attacks. For the organisation, the consequences include potential regulatory scrutiny under data-protection and pharmaceutical-quality regimes, loss of partner confidence, and the operational cost of investigating and remediating the intrusion. Because the number of affected people is unknown, the full scope of these risks cannot yet be quantified; the absence of that figure itself increases uncertainty for those who may be involved.

The claim of a scheduled leak date in late August 2024 further implies that any data the group holds may already be circulating or may soon become more widely available, heightening the need for vigilance rather than panic.

If your data was in this claimed breach

If you have reason to believe your information could be among the internal files associated with duopharmabiotech.com, begin with basic hygiene: change passwords on any accounts that reuse credentials linked to the company, enable multi-factor authentication wherever available, and monitor financial and email accounts for unexpected activity. Be especially alert to unsolicited messages that reference Duopharma Biotech or pharmaceutical business relationships, as such messages may be phishing attempts built on leaked contact data. Document any suspicious contacts and report them to the relevant authorities or to the organisation itself if a formal notification channel is provided.

Readers can also run a free exposure scan of their email address to check whether their information has already surfaced in known breach data sets. Such a scan does not confirm or rule out involvement in this specific incident, but it offers a practical starting point for understanding broader exposure and deciding what further steps are warranted while official details remain limited.

AICompiled with AI assistance from public sources and published under our editorial standards.